Public Views on Prescription Drug Costs: Regulation, Affordability and TrumpRx

(Authors: Audrey Kearney, Alex Montero, Julian Montalvo III, Isabelle Valdes, Ashley Kirzinger, and Liz Hamel for The Kaiser Family Foundation Published: Mar 13, 2026)

In recent weeks, the Trump administration has renewed focus on lowering the cost of prescription drugs in the U.S., including the launch of TrumpRx. The latest polling from KFF shows that about four in 10 U.S. adults (41%) say it is likely the Trump administration’s policies will lower prescription drug costs for people like them, but views are largely influenced by partisanship. Only the president’s base remains positive, with 79% of Republicans and 88% of Make America Great Again (MAGA) supporters saying it is likely the administration will lower prescription drug costs, while much fewer independents (35%) and Democrats (11%) say it is likely. But there is broad, bipartisan agreement that the government should be playing a bigger role when it comes to regulating prescription drug costs, with at least two-thirds of Republicans, Democrats, and independents saying there is not as much government regulation as there should be in this area. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.